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ABSTRACT
The explosive growth in genetic technology will quickly make possible an
unprecedented number of tests for genetically based conditions. A
necessary condition for the use of such tests without risk of harm to the
patient is that they are “accurate”. However, most discussions of test
accuracy in the literature have equivocated between two importantly
different meanings of the word. In particular, it must be kept in mind that
a high analytical accuracy does not imply a high diagnostic accuracy.
Questions about the diagnostic accuracy of genetic tests loom large at
present given our limited knowledge of the complex etiology of disease
and the distribution within the general population of the causal factors
involved. Our current inability to supply patients with accurate diagnosis
based on genetic information, however, is less problematic when
examined in the context of new reproductive technologies such as in vitro
fertilization (IVF) and intraplasmic sperm injection (ICSI).
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“For every complex problem, there is a simple, easy to understand,
incorrect answer.”
-- Albert Szent-Gyorgyi

I. INTRODUCTORY COMMENTS
The growth in genetic testing technology is nothing short of explosive.
The Human Genome Project, which aims to sequence all 100,000 human
genes, is currently ahead of schedule and should be complete by the
year 2001 -- some even predict that we will have the sequence for all
genes in all living organisms by 2015 if sequencing efforts continue to grow
at the present rate (1). Within the next 10 years, as many as 400 new
genetic screens are likely to become available, aided by development of
integrated circuit chips capable of performing thousands of hybridization
probes on a single minute sample of DNA. Already, more than 4 million
blood samples from newborn heel sticks are screened each year for
various genetic disorders (2).

Genetic screening is thus likely to be

increasingly viewed as a common and accepted aspect of modern
medicine, based in large part on the perception that offering patients
screening is itself a harmless enterprise, and may even be required as part
of the standard of care 1. However, offering genetic screening is often
only harmless to the extent that it provides an accurate basis for making
informed decisions about one’s condition. 2
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II. INFORMATION AND ACCURACY OF GENERALIZED GENETIC SCREENING
I do not mean to suggest that genetic screening is inherently evil, much
less that it is avoidable. It is also beyond the scope of the present work to
address all the various social and ethical issues that the widespread use of
genetic screening in the general population will surely raise: access to
insurance, privacy, social stigmatization, eugenics, etc. However, I do
want to draw attention to a problem with genetic screening when it is
applied to the general population which has not received as much
attention in the literature as it deserves 3.
The problem is that discussions of the accuracy of genetic testing often
equivocate between two distinct meanings of “accuracy”. With our
current state of knowledge, a high degree of analytic accuracy in a
genetic test does not imply a similarly high degree of diagnostic
accuracy 4. By “analytic accuracy” I mean the accuracy with which a
test identifies the presence of the gene it is designed to locate -- avoiding
both positive results when the gene is absent and negative results when
the gene is present. By “diagnostic accuracy” I mean the accuracy with
which the test can be used to make predictions about a patient’s
prognosis. For the sake of argument, let’s assume that we are only
discussing tests which have a 100% analytic accuracy. That is, we have
somehow managed to avoid the problems posed by laboratory error and
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we are testing directly for the gene in question, not a closely linked
marker 5. Even in this ideal case, interpreting the results of the test in a way
that is meaningful to patients will be extremely difficult for a long while to
come.
At its most basic, the reason for this can be stated as follows: the
presence of a particular gene associated with a medical condition does
not insure that one will develop the condition 6. There are three possible
explanations for this lack of “genetic determinism”: multiple mutations
(alleles) for a single gene, multiple genes, and gene-environment
interactions. If the genetic basis of a condition has many alleles and their
frequencies vary widely between populations, then the type of test
required and the way the results are interpreted are relative to the
population from which the patient comes in complex ways. If the
condition has multiple genes, then we will need to determine all or most
of the genes involved and test for each of them simultaneously to obtain
an accurate diagnosis. Finally, if the condition exhibits significant geneenvironment interaction -- as is the case with most complex medical
conditions and particularly those involving “propensity genes” (e.g.,
cancer, coronary disease, etc.) -- we must be able to assess the variation
of significant environmental factors within the patient population to be
screened in order to make diagnostic predictions 7.
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It is important to keep in mind that this is more than the obvious point
that, “one can never predict things with absolute certainty.” With current
techniques, it is very difficult even to assign an accurate probability to a
particular diagnosis 8, though this seems a minimum requirement for the
justification of testing in the first place. One way to illustrate the problem is
by looking at the procedure most often initially used to isolate a gene
associated with a medical condition. Since such conditions are typically
quite rare, the first step is to locate a population in which the condition is
unusually common so that we have more of a phenomenon to study.
Then, researchers conduct statistical analyses to see if there are any
regions of the chromosomes which seem to covary significantly with the
condition -- that is, if there are any pieces of genetic material one is
significantly more likely to have if one has the condition than if one is
healthy. Once we have located a segment of DNA that appears to
covary with the condition, we can use molecular techniques to refine the
analysis. In the ideal case, these efforts will isolate a single gene which is
then designated as “the gene for” the condition. At this point, we can
develop genetic tests to determine if individuals have the gene 9, but can
we make accurate diagnostic predictions about the likelihood of their
developing the condition?
Suppose, for example, I find that in populations of Eastern European
(Ashkenazi) Jews, there is a very high incidence of breast cancer
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associated with a particular gene (BRCA1). Fully 85% of Ashkenazi women
with BRCA1 will develop breast or ovarian cancer in their lifetimes. Now
suppose I produce a test for BRCA1 and administer it to women in the
general population. If a woman who is neither Jewish nor European tests
positive for BRCA1, do I tell her that she has an 85% chance of contracting
cancer? Such a prediction is justifiable only if one of two assumptions is
correct:
1) There are no other factors besides the BRCA1 gene which
significantly alter the likelihood of developing cancer.
2) There are other factors which significantly alter the likelihood of
developing cancer, but these have the same distribution in the
general population as they do in the Ashkenazi population and
therefore do not differentially affect the likelihood of developing
the condition from one population to the other.
The first assumption is almost certainly false for a condition like cancer
which probably involves multiple genes with multiple alleles and complex
gene-environment interactions all at once. So, is the second assumption
true? If we are honest, we should admit that we really don’t know; both
because we do not know all the causal factors which influence cancer
and because, even if we did know them all, we have not measured their
distribution within the general population. Moreover, the population in
which we conducted the initial study was attractive precisely because it
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was NOT representative -- in particular, it had an unusually high incidence
of the rare disorder and associated gene(s). But the same factors which
produced this biased distribution in the study population (e.g., inbreeding)
are almost certain to have skewed distributions of other factors as well. So
the study population is unlikely to have a “normal” distribution of whatever
additional factors may be causally influencing the condition -- whether
they be genetic, cytoplasmic or environmental. The diagnostic accuracy
of the test with respect to the general population is entirely dependent on
the questionable assumption of a uniform distribution of causal factors
and is thus suspect -- despite the fact that we have (ex hypothesi) a test
with perfect analytical accuracy.

III. CYSTIC FIBROSIS AS A CASE STUDY
Cystic Fibrosis (CF) makes a good case study for the type of problem I
want to highlight for several reasons. For one thing, it has a relatively
simple etiology as genetic conditions go in that there seems to be just a
single gene involved. For another, it is relatively common -- about 1 out of
every 2,500 whites of European descent is affected 10. Lastly, it is one of
the few genetic conditions for which there is data on the population
distribution of the alleles involved (as well as the effectiveness of
education programs).
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CF is a condition in which thickened secretions in the respiratory,
digestive and reproductive systems result in chronic respiratory infections,
loss of respiratory function, digestive difficulties and infertility. It can be an
extremely debilitating condition and is often fatal, though the median
survival has now climbed to forty years old and approximately one half of
CF patients survive into their fifties (with intensive therapy). It is caused by
various recessive autosomal mutations in the gene which codes for the
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, of
which there are known to be more than 300 alleles 11. Since the majority
of mutant alleles are carried by people who are heterozygous (and thus
don’t exhibit the recessive disease), as many as one in every thirty U.S.
citizens (3% of the general population) may carry at least a single copy of
a CF mutation.
CF can be diagnosed in three different ways: through an assessment of
symptomology/physiologic performance, through the sweat chloride test,
and through genetic testing for a known mutant allele. Since fully 85% of
CF cases occur in families with no known history of the condition, it has
been proposed as a desirable candidate for generalized screening of the
population (12, but see also 13).
As Table 1 shows, however, just about every combination of diagnostic
indicators has been documented 12. There is also no simple relationship
between particular genetic alleles and the severity of the disease (11, 15,
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16). Thus, on the basis of genetic tests and/or sweat chloride values, it is
very difficult to predict whether a patient will develop the condition and
how severely he will be affected. Lastly, there are large differences
between populations with respect to the relative frequency of the alleles
and quite different screens are often required for different populations.
Even for what most people intuitively consider a homogenous population,
white Europeans, genetic diversity is the rule rather than the exception.
For example, screening for just 4 alleles in Britain is sufficient to detect 85%
of CF cases -- but in Southern Europe, screening for as many as 60
mutations detects only 75% of the CF cases 13.
Therefore, even for a “single gene” condition like CF, it is not enough
simply to identify all the alleles which are associated with the condition.
We must also assess their distribution in various populations and reliably
determine into which population a patient should be classed. 14 All three
tasks present complex problems which require a great deal more work to
solve adequately 15.

IV. THE PSYCHOLOGY OF INFORMATION
Above and beyond the information problems discussed above, there
are additional problems with the way the genetic results will be
perceived. There is a strong psychological tendency to view numerical
information as being highly accurate, despite the fact that the actual

10
information content of such numbers can range from 0 (completely
uninformative) to 1 (perfect predictor). In the case of genetic screening,
the information content of numerical diagnostic predictions is typically
unknown or, at the very least, subject to debate. To be sure, this is not a
problem limited to the lay public as even professional logicians and
statisticians often make elementary errors in interpreting information -particularly statistical information (19).
However, in the context of genetic screening, this problem looms
particularly large. We wish patients to be actively involved with their own
treatment and require informed consent for any medical procedure done
to a patient that might inflict harm. The ideal case is for the patient to
assess the risks and benefits for herself and decide whether to undergo
the procedure. To what extent can this ideal be met in the case of
genetic screening?
The first question is, “Can the patient be made to understand the
relevant details of a highly technical procedure like genetic screening?”
The evidence suggests that, with a great deal of effort by trained genetic
counselors, they can (20). This is encouraging, though it must be kept in
mind that there is currently a severe shortage of trained counselors. Thus,
if screening becomes commonplace, it will be increasingly performed by
general practitioners whose training in genetics and probability is not of
uniformly high quality 16.
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The next question is, “Are people able to retain the information
accurately beyond the immediate context of testing?” Here, the
evidence is less encouraging. In one three year follow-up to large-scale
CF screening, it was found that 20% of those identified as carriers
incorrectly recalled the results of the testing. Moreover, of those who
correctly recalled the result, 46% interpreted it incorrectly as meaning that
they were only likely to be carriers (20). It has been suggested that this
problem may ultimately be correctable by changes in the educational
system to produce graduates who are better informed about genetics
and statistics 17, but this is certainly a very long term project.
The last question is, “Do people actually want the tests?” The answer to
this is complex. Offers of free genetic screening to members of the
general population typically result in very low response rates, suggesting
that many people have little desire to know their genetic status (23). On
the other hand, it’s been found that fully 70% of those offered screening in
person by a health professional accept (6). Whether a patient accepts a
test depends strongly on the mode of presentation 18, and this brings up
the issue of whether even the offer of genetic testing by a physician is, in
fact, a neutral act. It seems likely that such an offer will be perceived by
the patient as constituting at least an indication of safety and accuracy,
and perhaps even an endorsement of value. If so, this will significantly
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strengthen the perception that the resulting diagnostic prediction is highly
accurate.

V. GENETIC SCREENING AND REPRODUCTIVE TECHNOLOGY
A. Pre-natal Screening
One of the most obvious and compelling but also most controversial
applications of genetic screening is its use in pre-natal care. It is
compelling because we are deeply concerned with the health of our
children -- often more so than with our own (as any pediatrician can
testify). It is controversial because, although there is always the hope that
early detection will allow early intervention, this is currently quite rare 19
and thus the main outcome of a “bad” genetic result is termination of the
pregnancy.
Two techniques of obtaining tissue samples for genetic analysis are
currently widely used. Amniocentesis is performed at 14-16 weeks of
gestation and involves needle aspiration of amniotic fluid containing fetal
cells. The cells are then cultured and their DNA analyzed. Chorionic Villus
Sampling (CVS) is performed at 9-12 weeks gestation and involves
collection of cells from the chorion (either by catheter or needle), which
can then be immediately analyzed. CVS is a major improvement over
amniocentesis in that the procedure can be performed much earlier and
the results obtained more quickly (24 hours as opposed to 10-14 days).
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Both procedures are highly invasive and carry small but significant risk to
the fetus (approximately 1% risk of fetal loss). Moreover, some conditions
can not currently be detected at eight weeks (e.g., some neural tube
defects). For these reasons, it is unlikely that genetic screening using these
tissue collection techniques will ever become standard procedure for the
vast majority of pregnancies. However, this is all likely to change soon as
new techniques for isolating fetal cells from maternal blood samples
come on line (24). It is now possible to detect and isolate fetal cells in the
maternal blood as early as 9 weeks gestation 20.
As little as fifteen years ago, it would have been impossible to perform
genetic analysis on the vanishingly small amounts of DNA obtained from
such a tiny sample of cells, but the newly-developed Polymerase Chain
Reaction (PCR) technique is capable of amplifying DNA from a single cell
quickly and accurately. Moreover, as the Human Genome Project
reaches completion and more and more genes are identified, it will be
possible to screen very early fetal cells for their genetic contents. What
this means in practice is that soon there will be techniques which are
available very early in pregnancy and are no more invasive or dangerous
than a routine blood sample. Under these circumstances, it seems very
likely that they will quickly become an accepted part of standard care.

B. Pre-implantation Screening
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With In Vitro Fertilization (IVF), it is now possible to test extremely early
embryos for genetic conditions. In IVF, multiple donated eggs are
collected and mixed with donated semen in vitro. It is possible to remove
a single cell at the 4 or 8 cell stage of the resulting embryo and, using PCR,
amplify and analyze its genes. In fact, it is possible to detect some
genetic abnormalities in a single-celled zygote using Fluorescent In Situ
Hybridization (FISH). FISH involves treating the cell with fluorescent genetic
probes which will hybridize to some kinds of genetic abnormalities, making
the deformity visible under a microscope 21.
Although early detection is a major advantage, IVF is also extremely
invasive. The costs, both emotional and economic, are quite high -- with
success rates of approximately 14% per procedure and costs of $15,000
(2). IVF pre-implantation screening will thus remain a specialized
procedure for the present22.

C. Pre-fertilization Screening
Techniques for the screening of individual gametes are currently under
development. If techniques like FISH eventually make it possible to certify
samples of sperm or eggs as “defect free”, this would constitute the
ultimate in screening. For one thing, it offers advantages over screening
of the parents since, even if both parents are carriers of a recessive
condition, there is only a 25% chance the child will exhibit the condition
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(and a 50% chance the child will also be a carrier). For another, it avoids
the issue of termination of pregnancy since undesirable pregnancies will
not even be started. At the very least, the technique is likely to become
popular with sperm donated to sperm banks as the collection methods
are simple and artificial insemination is less invasive, cheaper and more
effective than IVF 23.

VI. SOME TENTATIVE CONCLUSIONS
Healthcare decisions in this country seem all too often to result from an
ad hoc synergy of special interests, without adequate consideration of
what is in the best interests of either the individual or the community 24. In
particular, it is often argued that, given the public interest in testing and
the enormous amount of money to be made from generalized screening,
the advent of routine genetic screens is simply a matter of time (27).
Despite calls from several professional bodies that genetic screening
should be preceded by careful pilot studies (2), the funding for these
studies is difficult to find. The only reason the CF follow-up studies were
commissioned was at the behest of the ELSI committee of the HGP, itself a
highly unusual and perhaps temporary entity.
To summarize, I have tried to establish the following points which must
be considered when discussing genetic screening of the general
population:
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1) Currently, the data we need to assess the diagnostic accuracy
for most genetic conditions is simply not available. Moreover, it is
difficult to secure the funding needed for such studies.

2) Members of the general public will nevertheless perceive testing
as diagnostically accurate, particularly if tests are offered as a
routine part of care by their physician. This will, in turn, drive the
development of more and more genetic tests by private
companies interested in the enormous profits to be had from
screening of the general public.

3) It is very difficult (though not impossible) to educate people
about the implications of genetic results, especially given the
current dearth of trained counselors. It is even more difficult to
insure that they retain the information for the extended periods of
time often necessary to make appropriate lifestyle or

treatment

decisions.
So, what can we conclude about genetic screening of the general
population? I would like to offer some tentative conclusions based on the
two notions of accuracy I have distinguished:
1) Individual patients are simply not in a position to evaluate the
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diagnostic import of genetic tests. As individuals, they can not
assess population level phenomena and as non-experts, they can
not be expected to follow all the technical minutia. The situation
seems analogous to the public release of new drugs: patients might
be interested in trying a new drug but we typically do not allow this
until we have had a chance to carefully assess its effectiveness and
possible side effects. Genetic screening of the general population
of adults should fall in the same category. To be sure, there will be
special situations -- for people in high risk populations, we have
more data on the distribution of causal factors and thus a better
grasp of the diagnostic accuracy. Moreover, a total ban on
screening would prevent the collection of precisely the data we
need to evaluate its effectiveness. However, to the extent that we
allow screening of members of the population not known to be at
high risk, it should be for the purpose of data collection only and
they should be treated as any other experimental subject.

2) In cases of pre-natal screening, the same information problems
apply as with the general adult population. However, to the extent
that early intervention may be possible, experimental evaluation of
early treatments for genetic conditions is certainly justified.
Moreover, allowing limited screening of fetuses may be a good
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way to generate the data needed to assess the diagnostic
accuracy of the screens. Of course, this would require extensive
follow-up after the initial screen to determine which children went
on to develop the condition and which did not.

3) Pre-implantation and pre-fertilization screening pose much less
severe problems with respect to diagnostic inaccuracy than those
associated with other screens of the general population. This is
because a selection often must be made as to which embryo(s) to
implant or which gamete(s) to employ. If a decision such as this
can not be avoided, and if there is no alternative means of
selection which is more informative, it is less problematic to rely on
information of uncertain diagnostic accuracy provided by current
genetic screening techniques. This is because the decision per se
does not have to be justified on the basis of the information, since a
decision of some sort is unavoidable. Of course, the precise form of
the decision is justified via the genetic information, but the
alternative is often to use either arbitrary or morally questionable
criteria (e.g., sex selection). Therefore, even if the genetic
screening turns out to be completely uninformative (which is
unlikely), it is hard to see how we are any worse off using it in these
cases.
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TABLE 1: PERMUTATIONS OF DIAGNOSTIC CRITERIA
IN CYSTIC FIBROSIS

CLASSIC
SYMPTOMS

SWEAT

GENETIC

STATUS

TEST

TEST

positive

positive

positive

classic CF

positive

positive

negative

occurs

positive

negative

positive

common

positive

negative

negative

common

negative

positive

positive

occurs

negative

positive

negative

occurs

negative

negative

positive

?

negative

negative

negative

health
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ENDNOTES
1

For example, The American College of Obstetrics and Gynecology

includes the offering of prenatal screening as part of the standard of care
(3). For a more detailed discussion of the evolution of standard of care as
it relates to testing, see 4, 5.
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2

For example, a bilateral radical mastectomy may (or may not) be a

justified procedure if one is at high risk for breast cancer. However, such a
procedure obviously becomes more unwarranted as the prognosis
becomes less certain.

3

An exception to this is the work of Benjamin Wilfrond (6, 7).

4

This problem is, in some sense, a transient one since it will be corrected

as our knowledge of the etiology of disease grows. However, this makes it
no less serious an issue. Moreover, the information required to resolve the
problem will be far more difficult to collect than many currently realize.

5

It should be noted, however, that a small amount of analytical error can

seriously erode the diagnostic accuracy of a test for rare conditions. For
example, even with a relatively common genetic disease such as Cystic
Fibrosis and a test with a 99% analytical accuracy, a positive result is
twenty times more likely to be due to test inaccuracy than the presence
of the gene.

6

For a related discussion concerning the causal nature of disease in

general and phenylketonuria in particular, see (8, 9)
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7

Whatever else it might do, widespread use of new cloning technologies

on humans would be an interesting test of the extent to which human
traits are the result of genes rather than environments. By holding the
genetic background constant and varying both the cellular and maternal
environment, variation in traits between donor and clone would be
attributable to differences in the environment -- at least more so than they
are at present.

I do not mean, of course, that it is difficult to calculate a probability, but

8

that it is difficult to defend such numbers as being justified, given our
current state of knowledge about the etiology of most genetic conditions.

9

Of course, the research does not stop here. Next we would want to

know (at least) the amino acid sequence of the protein, as well as its
three-dimensional confirmation, location and function within the cell.

10

The exact incidence figures cited varies from 1/4700 to 1/1000 because

different authors examine subtly different populations.

11

CFTR is a cAMP mediated chloride channel protein found in the plasma

membrane. Defects in this protein result in poor uptake of chloride ions by
the cells, which results in high levels of chloride in the sweat (10). Thus, the

27

sweat chloride test is currently considered the gold standard for CF
diagnosis. It should be noted that a single mutation, delta F508, seems to
account for a large majority of CF cases in whites (11).

12

This raises interesting questions about the nature of a disease – should it

be defined in terms of a symptomology, as was the case in earlier times;
or should identification of putative casual agents be considered primary
(see 14)?

13

see (16, 17). Note also that these are known cases of CF - it may be that

some cases of CF are not detected (due to very mild symptoms, etc.) and
thus are not reflected in these numbers.

14

This is not a simple matter of patient self-identification. As anyone who

has done family history research knows, people rarely have very clear
ideas about their ancestry more than two or three generations back.
What is worse, they often have incorrect ideas.

15

New techniques may be able to avoid some of these difficulties, at least

for single gene conditions, by a direct assay of protein function. It has
been found that many cells in easily accessible tissue (white blood cells,
for example) express minute amounts of mRNA from genes that they do

28

not “officially” express. These cells can be isolated from a blood sample,
the mRNA amplified and translated into protein, and the protein activity
directly assayed (18). Therefore, at least to some extent, it is not necessary
for us to know precisely which mutation is involved or even its precise
effect.

16

In fact, given the performance of many physicians on other genetic

tests like the APC test for familial adenomatus polyposis, the ability of the
average U.S. physician to act as a genetic counselor without specialized
training is in serious question (21).
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It has even been argued that, on certain conceptions of autonomy,

patients have an obligation to thoroughly inform themselves about testing
(22).
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Women often report that they find it difficult to refuse screening which is

offered as a routine part of prenatal care -- as with alpha fetaprotein tests
(4).
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For example, there is no conclusive evidence that CF screening enables

effective early intervention, despite much early optimism (7).
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20

There is the difficulty that cells from the fetuses of earlier pregnancies will

sometimes still be in the maternal bloodstream (25). This poses no
problem, of course, for first pregnancies and future refinements may allow
us to differentiate between the two cell lines before performing genetic
analysis.
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At present, this technique can only be used to detect relatively gross

abnormalities such as major chromosomal rearrangements or
aneupolidies.

22

New techniques in embryo collection involve using intrauterine lavage

to remove an embryo at the blastocyst stage (26). If these sorts of
procedures become routine, pre-implantation screening will as well.

23

Intracytoplasmic Sperm Injection (ICSI) even makes screening of

individual sperm before fertilization a possibility.

24

Wilfrond labels this the “extemporaneous model” of decision making

and advocates a more “evidentiary model” instead (6, 7).

